The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction;Renal disfonksiyonlu hastalarda kontrast nefropatisinin önlenmesinde nebivololün rolü

Anadolu Kardiyoloji Dergisi

Volumn 11, Issue 7, 2011, Pages 613-617

  Avci, Eyüp ^b   Yeşil, Murat ^a   Bayata, Serdar ^a   Postaci, Nursen ^a   Arikan, Erdinç ^a   Cirit, Mustafa ^a  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Balikesir State Hospital   (Turkey)

Author keywords

Beta blocker; Contrast induced nephropathy; Nebivolol; Renal dysfunction

Indexed keywords

ACETYLCYSTEINE; CREATININE; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; METOPROLOL; NEBIVOLOL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RENAL PROTECTION; STABLE ANGINA PECTORIS;

ADULT; AGED; AGED, 80 AND OVER; BENZOPYRANS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATININE; ETHANOLAMINES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; PROTECTIVE AGENTS; VASODILATOR AGENTS;

EID: 80054694709     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: 10.5152/akd.2011.164     Document Type: Article

References (26)

1. Weinrauch LA, Healy RV, Leland OS Jr, Goldstein HH, Kassissieh SD, Libertino JA, et al. Coronary angiography and acute renal failure in diabetic azotemic nephropathy. Ann Intern Med 1977; 86: 56-9.
2. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320: 143-9. [CrossRef]
3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103: 368-75. [CrossRef]
4. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20: 1542-50. [CrossRef]
5. Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94: 1069-75. [CrossRef]
6. Myers SI, Wang L, Liu F, Bartula LL. Iodinated contrast induced renal vasoconstriction is due in part to the down regulation of renal cortical and medullary nitric oxide synthesis. J Vasc Surg 2006; 44: 383-91. [CrossRef]
7. Pannu N, Wiebe N, Tonelli M:Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295: 2765-79. [CrossRef]
8. Duranay M, Kanbay M, Akay H, Ünverdi S, Sürer H, Altay M, et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract 2010; 114: 213-7. [CrossRef]
9. Toprak Ö, Cirit M, Tanri{dotless}sev M, Yazi{dotless}ci{dotless} C, Canoz Ö, Sipahioǧlu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008; 23: 853-9.
10. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation betaadrenergic blocker. Ann Pharmacother 2006; 40: 1353-60. [CrossRef]
11. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829-48. [CrossRef]
12. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Eng J Med 1994; 331: 1449-50. [CrossRef]
13. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000; 11: 177-82.
14. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidants enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-15. [CrossRef]
15. Sheridan AM, Bonventre JV. Pathophysiology of ischemic acute renal failure. Contrib Nephrol 2001; 132; 7-21.
16. Bakris GL, Gaber AO, Jones JD. Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium. Radiology 1990; 175: 57-60.
17. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis. Hypertonic versus oxidative stress. Invest Radiol 2002; 37: 428-34. [CrossRef]
18. Rihal CS, Textor SC, Grill DE, Perger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-64. [CrossRef]
19. Toprak Ö, Cirit M, Esi E, Postaci{dotless} N, Yeşil M, Bayata S. Hyperuricemia as a risk factor for contrast-i{dotless}nduced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv 2006; 67: 227-35. [CrossRef]
20. Toprak Ö, Cirit M, Yeşil M, Byrne DW, Postaci{dotless} N, Bayata S, et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res 2006; 29: 2-9. [CrossRef]
21. Cirit M, Toprak Ö, Yeşil M, Bayata S, Postaci{dotless} N, Pupim L, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104: 20-7. [CrossRef]
22. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high-and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-8.
23. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Eng J Med 1994; 331: 1416-20. [CrossRef]
24. Greven J, Gabriels G. Effect of nebivolol, a novel beta 1-selective adrenoreceptor antagonist with vasodilating properties on kidney function. Arzneimittelforschung 2000; 50: 973-9.
25. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12: 451-9. [CrossRef]
26. Brehm Br, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000; 36: 401-3. [CrossRef]